Get the Stockscreener App
105.11
0.75%
0.785
Pre-market:
105.10
-0.005
-0.00%
Lantheus Holdings Inc stock is traded at $105.11, with a volume of 528.51K.
It is up +0.75% in the last 24 hours and up +0.07% over the past month.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
See More
Previous Close:
$104.32
Open:
$105
24h Volume:
528.51K
Relative Volume:
0.56
Market Cap:
$6.84B
Revenue:
$1.54B
Net Income/Loss:
$233.56M
P/E Ratio:
31.22
EPS:
3.3669
Net Cash Flow:
$348.64M
1W Performance:
-0.83%
1M Performance:
+0.07%
6M Performance:
+63.59%
1Y Performance:
+41.25%
1-Day Range:
$103.70
$105.94
1-Week Range:
$100.84
$106.98
52-Week Range:
$47.25
$111.86
Lantheus Holdings Inc Stock (LNTH) Company Profile
Name
Lantheus Holdings Inc
Sector
Phone
978 671-8001
Address
331 TREBLE COVE ROAD, NORTH BILLERICA, MA
Compare LNTH vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LNTH
Lantheus Holdings Inc
|
105.11 | 6.84B | 1.54B | 233.56M | 348.64M | 3.3669 |
TAK
Takeda Pharmaceutical Co Adr
|
16.73 | 53.43B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
10.11 | 44.52B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.22 | 37.52B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.91 | 32.24B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
529.05 | 22.46B | 3.17B | 1.29B | 1.01B | 27.09 |
Lantheus Holdings Inc Stock (LNTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-26-26 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-12-25 | Upgrade | Truist | Hold → Buy |
| Oct-08-25 | Downgrade | Goldman | Buy → Neutral |
| Aug-12-25 | Downgrade | Truist | Buy → Hold |
| Dec-18-24 | Initiated | Goldman | Buy |
| Sep-03-24 | Initiated | Redburn Atlantic | Buy |
| Jul-10-24 | Reiterated | JMP Securities | Mkt Outperform |
| Dec-18-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-04-23 | Initiated | TD Cowen | Outperform |
| Sep-29-23 | Initiated | William Blair | Outperform |
| Mar-08-23 | Initiated | JMP Securities | Mkt Outperform |
| Nov-30-22 | Initiated | SVB Leerink | Outperform |
| Oct-13-22 | Initiated | Mizuho | Buy |
| May-09-22 | Initiated | B. Riley Securities | Buy |
| Apr-13-22 | Initiated | Truist | Buy |
| Feb-01-21 | Initiated | SVB Leerink | Outperform |
| Jun-29-20 | Resumed | Jefferies | Buy |
| Aug-16-19 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Nov-02-17 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Nov-08-16 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-23-16 | Resumed | Credit Suisse | Neutral |
| Feb-24-16 | Reiterated | RBC Capital Mkts | Outperform |
| Dec-11-15 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-30-15 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jul-20-15 | Initiated | Credit Suisse | Outperform |
| Jul-20-15 | Initiated | Jefferies | Buy |
| Jul-20-15 | Initiated | RBC Capital Mkts | Outperform |
| Jul-20-15 | Initiated | Robert W. Baird | Outperform |
| Jul-20-15 | Initiated | Wells Fargo | Outperform |
View All
Lantheus Holdings Inc Stock (LNTH) Latest News
LANTHEUS HOLDINGS INC : TRUIST SECURITIES RAISES TARGET PRICE TO $125 FROM $115 - Bitget
LNTH Maintained by Truist Securities -- Price Target Raised to $125 - GuruFocus
RadioMedix appoints Brian Markison to board of directors By Investing.com - Investing.com South Africa
Lantheus Holdings Is Maintained at Market Outperform by Mizuho - Moomoo
LNTH Maintained by Mizuho -- Price Target Raised to $120 - GuruFocus
3 Reasons to Avoid LNTH and 1 Stock to Buy Instead - Yahoo Finance
Lantheus Holdings Inc (HAM:0L8) Stock Price, Trades & News - GuruFocus
Lantheus Holdings, Inc. (LNTH) Stock Analysis: A 4.44% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Lantheus (LNTH) Q4 2024 earnings summary - Quartr
Lantheus (LNTH) Q3 2025 earnings summary - Quartr
Lantheus (LNTH) M&A Announcement Summary - Quartr
B. Riley Securities Maintains Lantheus(LNTH.US) With Buy Rating, Raises Target Price to $129 - Moomoo
B. Riley Adjusts Price Target on Lantheus Holdings to $129 From $97, Maintains Buy Rating - Moomoo
LNTH Maintained by B. Riley Securities -- Price Target Raised to $129 - GuruFocus
Is Lantheus Holdings Inc (LNTH) Overvalued After 3.2% Rally? GF - GuruFocus
(LNTH) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Lantheus Holdings Inc focuses on diagnostic imaging growth - ad-hoc-news.de
Lantheus Holdings Inc (LNTH) Stock Down 6.4% but Still Overvalued -- GF Score: 82/100 - GuruFocus
Lantheus Holdings stock hits 52-week high at 90.5 USD - Investing.com
Lantheus Q1 2026 slides: regulatory wins fuel growth transition - Investing.com
LNTHLantheus Holdings Inc Latest SEC Filings - Finviz
Did FDA’s Facility-Related LNTH-2501 Delay and Russell Additions Just Reframe Lantheus Holdings’ (LNTH) Risk Profile? - Sahm
LNTH DEADLINEFINAL REMINDER: Bronstein, Gewirtz & Grossman LLC - The National Law Review
Lantheus Holdings Inc focuses on diagnostic imaging and radiopharmaceutical growth - Ad Hoc News
Lantheus receives complete response letter for LNTH-2501 - MSN
Lantheus Holdings stock hits 52-week high at 111.52 USD By Investing.com - Investing.com South Africa
Lantheus Holdings stock hits 52-week high at 111.52 USD - Investing.com
LNTH Reiterated by Citizens -- Price Target Maintained at $115 - GuruFocus
What's Going On With Lantheus Stock Monday?Lantheus Holdings (NASDAQ:LNTH) - Benzinga
Lantheus stock holds at Market Outperform despite FDA setback By Investing.com - Investing.com South Africa
Lantheus stock holds at Market Outperform despite FDA setback - Investing.com
Lantheus Holdings, Inc. (LNTH) Stock Analysis: Strong Buy Ratings Amid Impressive ROE and Expanding Diagnostic Portfolio - DirectorsTalk Interviews
Concentrix, AeroVironment And 3 Stocks To Watch Heading Into Monday - Benzinga
Lantheus Holdings, Inc.(NasdaqGM: LNTH) added to Russell 2000 Growth-Defensive Index - marketscreener.com
Lantheus Holdings, Inc.(NasdaqGM: LNTH) added to Russell 2000 Defensive Index - marketscreener.com
LNTH SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
LNTH Investors Have Opportunity to Lead Lantheus Holdings, Inc. C - The National Law Review
Bronstein, Gewirtz & Grossman, LLC (LNTH) Investigation: Bronstei - The National Law Review
LNTH STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Levi & Korsinsky Helps Shareholders SueWallSt After Lantheus Holdings, Inc. Stock Drops - The National Law Review
LNTH INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Liquidity Mapping Around (LNTH) Price Events - Stock Traders Daily
William Blair Maintains Lantheus(LNTH.US) With Buy Rating - Moomoo
FDA issues complete response letter for Lantheus’ NET imaging drug By Investing.com - Investing.com Nigeria
Lantheus (LNTH) Faces FDA Response on LNTH-2501 Application - GuruFocus
Lantheus (LNTH) Faces Setback with FDA Response on LNTH-2501 - GuruFocus
FDA issues complete response letter for Lantheus’ NET imaging drug - Investing.com
US FDA declines Lantheus’ tumor imaging kit over third-party manufacturing issues - Reuters
Lantheus stock falls after FDA rejects drug application By Investing.com - Investing.com South Africa
Lantheus stock falls after FDA rejects drug application - Investing.com
Lantheus Gets FDA Complete Response Letter for LNTH-2501 - Moomoo
Lantheus Holdings Inc Stock (LNTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.08%
1.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):